Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process
Etienne Buscail, Thomas Cauvin, Benjamin Fernandez, Camille Buscail, Marion Marty, Bruno Lapuyade, Clement Subtil, Jean-Philippe Adam, Véronique Vendrely, Sandrine Dabernat, et al.

To cite this version:
Etienne Buscail, Thomas Cauvin, Benjamin Fernandez, Camille Buscail, Marion Marty, et al.. Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process. BMC Surgery, BioMed Central, 2019, 19 (1), pp.115. 10.1186/s12893-019-0580-y. hal-02553836

HAL Id: hal-02553836
https://hal.inrae.fr/hal-02553836
Submitted on 24 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Intraductal papillary mucinous neoplasms of the pancreas and European guidelines: importance of the surgery type in the decision-making process

Etienne Buscail1,6,7*, Thomas Cauvin1,6,7, Benjamin Fernandez1,7, Camille Buscail2, Marion Marty3, Bruno Lapuyade4, Clément Subtil5, Jean-Philippe Adam1, Véronique Vendrely6, Sandrine Dabernat6, Christophe Laurent1,5,7 and Laurence Chiche1,6,7

Abstract

Background: The European Consensus 2018 established a new algorithm with absolute and relative criteria for intraductal papillary mucinous neoplasms of the pancreas (IPMN) management. The aim of this study was to validate these criteria and analyse the outcomes in function of the surgical procedure and IPMN subtype.

Methods: Clinical, radiological and surgical data (procedure, morbidity/mortality rates) of patients who underwent surgery for IPMN between 2007 and 2017. The predictive value of the different criteria was analysed.

Results: 124 patients (men 67%; mean age 65 years) underwent surgery for IPMN (n = 62 malignant tumours; 50%). Jaundice, cyst ≥ 4 cm and Wirsung duct size 5–9.9 mm or ≥ 10 mm were significantly associated with malignancy (4.77 < OR < 11.85 p < 0.0001). The positive predictive value of any isolated criterion ranged from 71 to 87%, whereas that of three relative criteria together reached 100%. The mortality and morbidity (grade III-IV complications according to the Dindo-Clavien classification) rates were 3 and 8%, respectively. Morbidity/mortality after duodenopancreatectomy and total pancreatectomy were significantly higher for benign IPMN (p = 0.01).

Conclusion: Considering the morbidity associated with extended surgery, particularly for benign IPMN, the results of the present study suggest that high-risk surgery should be considered only in the presence of three relative criteria and including the surgery type in the decision-making algorithm.

Keywords: IPMN, Pancreatic resection, European guidelines, Post-operative morbidity

Background

Intraductal papillary mucinous neoplasm of the pancreas (IPMN) is characterized by adenomatous proliferation of the pancreatic duct epithelium that may involves the main pancreatic duct, the branch ducts, or both [1]. Accordingly, IPMNs are classified in three groups: main pancreatic duct (MD), branch duct (BD), and mixed tumours. IPMN malignant transformation occurs in 25–70% of cases, of which 15–43% are invasive, especially in the case of MD and mixed IPMN [2–4]. Surgical resection remains the best treatment to avoid this unfavourable outcome. However, two major problems remain: first, many BD IPMN (75–82%) will never progress to malignancy; and second, pancreatic surgery inherent morbidity is not negligible [2, 3]. Therefore, it is crucial to identify the patients who will actually need surgical resection.

Several guidelines have been established to define the surgery criteria, depending on the presence or not of “ worrisome signs” and “high risk stigmata of malignancy” (i.e., high grade dysplasia and invasive carcinoma) [5–8]. In these algorithms, the patient’s performance occurs in 25–70% of cases, of which 15–43% are invasive, especially in the case of MD and mixed IPMN [2–4]. Surgical resection remains the best treatment to avoid this unfavourable outcome. However, two major problems remain: first, many BD IPMN (75–82%) will never progress to malignancy; and second, pancreatic surgery inherent morbidity is not negligible [2, 3]. Therefore, it is crucial to identify the patients who will actually need surgical resection.

Several guidelines have been established to define the surgery criteria, depending on the presence or not of “worrisome signs” and “high risk stigmata of malignancy” (i.e., high grade dysplasia and invasive carcinoma) [5–8]. In these algorithms, the patient’s performance...
status is taken into account to determine the surgery benefit/risk ratio. Recently, several European societies (i.e., the European Study Group on Cystic Tumours of the Pancreas, United European Gastroenterology, European Pancreatic Club, European-African Hepato-Pancreato-Biliary Association, European Digestive Surgery, and European Society of Gastrointestinal Endoscopy) published updated evidence-based guidelines for the management of pancreatic cystic neoplasms [9, 10].

In this study, we retrospectively analysed the clinical, imaging and pathological data of patients with IPMN who underwent surgery to evaluate: i) the diagnostic value of the relative and absolute European criteria or IPMN surgical resection; and ii) the post-operative morbidity and mortality rates.

Methods
Patients and inclusion criteria
Between January 2007 and December 2017, 720 patients underwent surgery for pancreatic adenocarcinoma or IPMN. Among them, all consecutive patients with BD, MD or mixed IPMN eligible for pancreatic surgery (i.e., resectable IPMN at imaging) and who underwent resection were included in the present study. All resected IPMN were histologically proven.

This study was conducted according the French rules (Bioethics law of November 2016 – research category number 3), and the Comité National Informatique et Liberté (French Data Protection Authority) recommendations for the anonymous extraction and treatment of data. According to these rules, due to the study retrospective nature, it was not necessary to obtain the patients’ informed consent for the analysis of their personal data. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th version, 2008) and was approved by the Bordeaux university hospital ethics committee (Direction recherche Clinique centre hospitalier universitaire de Bordeaux). This study followed the STROBE statement guidelines.

Collected data
Since January 2005, all clinical, radiological and pathological data of patients undergoing pancreatic surgery at our centre are prospectively recorded in a dedicated database. We extracted the main clinical and radiological data, including most of the criteria retained by the recent European Consensus: age, sex, medical history, circumstances of diagnosis and symptoms related to IPMN, date of diagnosis, and biological data (including hepatic enzymes, blood lipase level), as well as the results of computerized tomodensitometry (CT) (helical triple-phase CT, each pancreatic section was effectively collimated into 3-mm sections at a pitch of 1.5), magnetic resonance cholangiopancreatography (MRCP) (1-T superconducting magnetic-resonance unit Magnetom Impact, Siemens, Erlangen, Germany, using a half-Fourier single-shot turbo spin-echo sequence), endoscopic ultrasound (EUS), and fine-needle aspiration biopsy (FNA) (Olympus, Hamburg, Germany). The collected imaging data were: maximal diameter of the MD and side branch duct cyst, tissue component/thickening surrounding the MD or BD, and mural nodules with a size ≥5 mm.

According to the 2018 European guidelines, all absolute (tumour-related jaundice, presence of contrast-enhancing mural nodule ≥5 mm, solid mass, MD size ≥10 mm) and relative (rapid growth rate, MD size between 5 and 9.9 mm, cyst diameter ≥40 mm, new onset of diabetes, acute pancreatitis caused by IPMN) criteria for surgery were analysed, with the exception of positive cytology for malignant/high grade dysplasia, increased levels of CA 19.9 (≥37 Ul/ml) and enhancing mural nodules <5 mm in size due to too many missing data.

Surgical data
Type of resection and postoperative complications were collected for patients who underwent surgery. All surgical indications were discussed and validated by our pancreas disease multidisciplinary group [5, 11]. In all cases, the surgical approach was surgical resection with appropriate lymphadenectomy, and frozen section analysis of the resection margins. The surgical approaches were classified as follow: distal pancreatectomy, pancreatoduodenectomy, total pancreatectomy, enucleation, and median pancreatectomy. Surgical morbidity was defined by the occurrence of grade III, IV or V postoperative complications, according to the classification by Dindo and Clavien [12]. Grade III includes complications that require surgical, endoscopic or radiological intervention, with or without general anaesthesia. Grade IV includes life-threatening complications that require management in an intensive care unit. Grade V complications cause postoperative death. Pancreatic fistula and post-operative haemorrhage were both defined according to the International Study Group of Pancreatic Surgery (ISGPS) classification [13, 14]. The macroscopic pathological analysis followed a standardized protocol in which the pancreas tissues were cut in serial sections that include the tumour up to the inked margins.

Histopathological data
The resected tumour pancreatic tissue specimens were characterized and subtyped according to the Verona Consensus Meeting recommendations [1]. IPMN was classified in three subtypes: MD, BD and mixed. Following the 2010 World Health Organization criteria, high-grade dysplasia and invasive adenocarcinoma were considered malignant, whereas low grade dysplasia were considered
benign IPMN [15]. The tumour cytological subtype was also reported (oncocytic, gastric, intestinal, hepatobiliary).

**Statistical analyses**
Qualitative and quantitative data (Student’s-t, $\chi^2$, exact Fisher tests) were analysed using the GraphPad-Instat and GraphPad-Prism 6.0a software programs (GraphPad Software Inc. San Diego, CA, USA). To identify independent predictors of malignancy, univariate and multivariate logistic regression analyses were performed using logistic regression tests with the SAS software (version 9.4, SAS institute, Cary, NC, USA). A $p$-value < 0.05 was considered significant. Due to the retrospective design of the study a post-hoc analysis was performed to evaluate the power of the study. The power analysis was performed using G-power software 3.1.9.2.

**Results**
**General characteristics, pre-operative imaging data and surgical procedures**
In total, 124 consecutive patients were included (18% of all patients who underwent pancreatic resection in our department during the study period) (Fig. 1, panel A). The main characteristics and the imaging data at diagnosis and during the pre-surgery follow-up of these 124 patients and of the subgroup who had duodenopancreatectomy or total pancreatectomy ($n = 75$) are summarized in Table 1. The patients’ performance status was relatively good (American Society of Anaesthesiologists physical status: 1–2 for most of them), the most frequent symptoms were acute pancreatitis and abdominal pain (upper part, without hyperlipasemia), 36% of patients were asymptomatic, and 71% of patients had at least two different types of imaging exams. In Table 2 are detailed the indications for surgery, surgical procedures, post-operative complications, pathological findings and macroscopic subtyping (BD IPMN in 33 patients, MD IPMN in 46, and mixed form in 45; 73% of patients had MD or mixed IPMN). Table 3 shows the histological classification in term of malignancy, and the cytological subtyping depending on the anatomical involvement. Malignancy rate and histological subtype distribution were comparable in BD and MD/mixed IPMN samples. Comparison of the diagnostic performances of each imaging technique for recognizing BD and MD/mixed IPMN (Additional file 1: Table S1 and Additional file 2: Table S2) indicated that CT was more suitable for the diagnosis of BD IPMN, while MRCP was the
most accurate imaging tool for the diagnosis of MD/mixed forms. EUS was slightly less accurate for both IPMN forms.

### Univariate and multivariate analyses of the absolute and relative European consensus criteria for predicting malignant IPMN

Analysis of the performance of each malignancy criterion retained by the European consensus using univariate and multivariate analyses (Table 4) showed that among the absolute criteria, jaundice and MD size ≥10 mm were significantly associated with malignancy (OR 11.85 and 7.52, respectively). Among the relative criteria, only cyst size ≥3 cm, which was considered as a worrisome feature in the 2017 Fukuoka consensus guideline, was significantly associated with malignancy, but with a lower odds ratio (2.78). Finally, absence of symptoms, and MD size < 5 mm were associated with benign tumours (0.0005 < p < 0.0001 – relative risk 2.21 to 3.25).

### Specificity, sensitivity and predictive values of the absolute and relative criteria

Analysis of the predictive diagnostic values of the absolute and relative criteria of the recent European Consensus

### Table 1 Clinical characteristics at diagnosis and laboratory/imaging exams of all patients with IPMN who underwent surgery (n = 124) and of the subgroup who had duodenopancreatectomy or total pancreatectomy (n = 75)

| Variables | All type of resection | Whipple procedure and total pancreatectomy | Distal pancreatectomy | P * |
|-----------|-----------------------|--------------------------------------------|-----------------------|-----|
| Age (median; range) | 66.1 (67; 28–84) | 69.2 (68; 53–80) | 63.8 (66.5; 28–84) | 0.1 |
| Men, n (%) | 60 (48) | 39 (52) | 19 (15) | 0.3 |
| ASA score | 1 | 38 (31) | 25 (34) | 12 (26) | 0.9 |
| | 2 | 81 (65) | 48 (64) | 30 (66) | 0.7 |
| | 3 | 5 (4) | 2 (2.5) | 3 (6) | 0.2 |
| | 4–5 | 0 | 0 | 0 | 0.4 |
| First symptoms |  |  |  |  |
| Acute pancreatitis | 23 (18.5) | 14 (18) | 9 (20) | 0.9 |
| Jaundice | 8 (6.5) | 8 (10.5) | 0 | 0.9 |
| New onset of diabetes | 8 (6.5) | 8 (10.5) | 0 | 0.9 |
| Weight loss | 8 (6.5) | 6 (8) | 2 (4) | 0.7 |
| Diarrhoea and/or steatorrhea | 3 (2.5) | 3 (4) | 0 | 0.3 |
| Signs of chronic pancreatitis | 6 (5) | 7 (9.5) | 0 | 0.2 |
| Abdominal pain | 23 (18.5) | 14 (18) | 9 (20) | 0.9 |
| No symptom | 45 (36) | 22 (29) | 20 (45) | 0.1 |
| Serum CA 19–9 (n = 33; 27%) |  |  |  |  |
| Normal | 21 (63) | 12 (60) | 9 (20) | 0.7 |
| Elevated | 12 (37) | 8 (40) | 4 (9) |  |
| CT | 106 (86) | 65 (86) | 41 (90) | 0.5 |
| MRCP | 74 (59) | 44 (59) | 30 (66) | 0.5 |
| EUS | 68 (53) | 39 (52) | 25 (56) | 0.8 |
| (EUS-FNA) | (29; 43%) | (20; 51%) | (9; 20%) |  |
| At least two radiologic investigations | 89 (71) | 39 (52) | 45 (100) |  |
| MRCP + CT | 57 (46) | 28 (37) | 29 (64) |  |
| EUS + CT | 56 (45) | 33 (44) | 23 (51) |  |
| EUS + MRCP | 45 (36) | 25 (34) | 20 (45) |  |
| EUS + CT + MRCP | 34 (27.5) | 20 (27) | 14 (31) |  |

ASA: American Society of Anaesthesiology; CT-scan: computerized tomodensitometry; MRCP: magnetic resonance cholangiopancreatography; EUS: endoscopic ultrasound; FNA: fine needle aspiration

* t-test with Welch’s correction for age; fisher exact test for the other variables
(Table 5) showed that all absolute criteria displayed high specificity (from 84 to 97%) and similar predictive diagnostic values, but low sensitivity. The positive predictive value (PPV) and negative predictive value (NPV) ranged from 53 to 71% and from 50 to 55%, respectively. Combining two or three absolute criteria did not increase these values.

Table 2 Indications for surgery, surgery type and complications, and pathology analysis results of the surgically removed IPMN

| Variables                             | All resection types N = 124 N (%) | Whipple procedure and total pancreatectomy N = 75 N (%) | Distal pancreatectomy N = 45 N (%) | p Fisher exact test |
|---------------------------------------|-----------------------------------|--------------------------------------------------------|-----------------------------------|--------------------|
| Indication for surgery               |                                   |                                                        |                                   |                    |
| Symptoms                              | 42 (34): Acute pancreatitis N = 26 | 30 (40): Acute pancreatitis N = 14                   | 12 (27): Acute pancreatitis N = 12 | 0.1                |
| Jaundice                              | 65 (53): Jaundice N = 8           | 37 (49.5): Jaundice N = 8                             | 24 (53): Jaundice N = 0           | 0.7                |
| Imaging features                      | Pain and/or new onset of diabetes N = 8 |                                           |                                   |                    |
| (From Sendai and Fukuoka consensus)   |                                   |                                                        |                                   |                    |
| Progression criteria                  | 17 (13)                           | 8 (11)                                                | 9 (20)                            | 0.1                |
| Procedures                            |                                   |                                                        |                                   |                    |
| Pancreatoduodenectomy                 | 56 (45)                           |                                                        |                                   |                    |
| Distal pancrectectomy                 | 45 (36)                           |                                                        |                                   |                    |
| Enucleation                           | 3 (2.5)                           |                                                        |                                   |                    |
| Total pancreatectomy                  | 19 (15)                           |                                                        |                                   |                    |
| Central pancreatectomy                | 1 (0.5)                           |                                                        |                                   |                    |
| Post-operative complications          |                                   |                                                        |                                   |                    |
| Biochemical leak                      | 39 (31)                           | 15 (27)                                               | 20 (44)                           |                    |
| Grade B pancreatic fistula            | 6 (5)                             | 5 (9)                                                 | 1 (2)                             |                    |
| Grade C pancreatic fistula            | 5 (2.5)                           | 5 (9)                                                 | 0                                 |                    |
| Post-operative haemorrhage (**)       | 6 (5)                             | 4 (5.5)                                               | 2 (4)                             |                    |
| Dindo-Clavien III-IV                  | 15 (12)                           | 14 (18)                                               | 1 (2)                             |                    |
| Dindo-Clavien V                       | 4 (3)                             | 3 (4)                                                 | 1 (2)                             |                    |
| Overall morbidity (**)                | 36 (29)                           | 31 (41)                                               | 5 (12)                            | 0.0001             |
| Pathology: Macroscopic                |                                   |                                                        |                                   |                    |
| Branch duct                           | 33 (26.5)                         | 23 (31)                                               | 6 (13)                            |                    |
| Main duct                             | 46 (37)                           | 27 (36)                                               | 19 (43)                           | 0.01               |
| Mixed                                 | 45 (36.5)                         | 25 (34)                                               | 20 (44)                           | (Branch duct vs Main duct and mixed) |
| Pathology: Microscopic                |                                   |                                                        |                                   |                    |
| Low grade dysplasia                   | 51 (41)                           | 20 (26)                                               | 28 (62)                           | 0.01               |
| Intermediate dysplasia                | 11 (9)                            | 9 (12)                                                | 0                                 |                    |
| High grade dysplasia                  | 25 (20)                           | 18 (24)                                               | 7 (14)                            | 0.01               |
| Invasive carcinoma (****)             | 37 (30)                           | 28 (38)                                               | 9 (20)                            | (Low and intermediate dysplasia vs high grade dysplasia/Invasive carcinoma) |
| Pathology: Subtyping                  |                                   |                                                        |                                   |                    |
| Gastric                               | 15 (12.5)                         | 6 (8)                                                 | 9 (20)                            |                    |
| Intestinal                            | 34 (27)                           | 26 (35)                                               | 8 (18)                            |                    |
| Hepatobiliary                         | 56 (45)                           | 32 (43)                                               | 21 (47)                           |                    |
| Oncocytic                             | 5 (4)                             | 3 (4)                                                 | 1 (2)                             |                    |
| Other                                 | 14 (11.5)                         | 8 (11)                                                | 6 (13)                            |                    |

* Follow up included clinical and CT scan evaluations at least every 6 months (median follow-up 12 month (range 6–17)
**: Grade A n = 2, Grade B n = 2, Grade C n = 2
***: Overall morbidity includes Grade B and C fistula, post-operative haemorrhage and Dindo-Clavien grade III-IV-V complication
****: Well-differentiated n = 16 (43%); moderately differentiated n = 18 (48%); poorly differentiated n = 3 (9%)
Similarly, the sensitivity of all relative criteria was low, but their specificity ranged from 66 to 90%. The best predictive values were observed for cyst $\geq 4$ cm (PPV 81%, NPV 66%), followed by MD size between 5 and 9.9 mm (PPV 58%, NPV 55%) and acute pancreatitis (PPV 54%, NPV 51%). Combining three relative criteria strongly increased these values, especially specificity and PPV that reached 100%.

The same analysis performed only in the subgroup of patients who underwent pancreaticoduodenectomy or total pancreatectomy gave similar or lower values compared with the entire cohort (Table 5).

The post-hoc analysis was based on our primary outcome (that is the improvement of the sensitivity against the usual criteria for diagnosis). Given a first-species risk of 5%, an increased sensitivity of 35% and our sample size ($N=124$) and the power of our study was estimated at 97.3%.

Post-operative complications
In this population, the overall surgical morbidity rate was 15% ($n=19$), and the mortality rate was 3% ($n=4$). Grade I and II and grade III-V complications were significantly more frequent in the subgroup with pancreaticoduodenectomy and total pancreatectomy than in the whole population ($p < 0.0001$, relative risk 6.03) (Table 2). Analysis of the post-operative complications depending on the final histology (benign versus malignant IPMN) did not find any difference between benign and malignant IPMN in the whole population ($n=124$) (Fig. 1, panel B) and in the subgroup with distal pancreatectomy (Fig. 1, panel C). Conversely, in the subgroup with pancreaticoduodenectomy and total pancreatectomy ($n=75$), complications were significantly more frequent in patients with benign IPMN than with malignant IPMN ($p = 0.01$) (Fig. 1, panel D, and Additional file 3: Table S3).

**Discussion**

IPMN have a significant potential for malignancy, particularly the MD and mixed forms (50%) and to a lesser extent the BD forms (10 to 15%) [3, 16–19]. Decision-making in IPMN is a real challenge [20], because surgery is the only curative treatment of malignant IPMN. Therefore, for patients with IPMN, it is always necessary: i) to collect all information that might help to predict the risk of malignancy; ii) to choose the type of surgical procedure, depending on the IPMN location; and iii) to weigh the benefit/risk ratio of pancreatectomy.

The Fukuoka consensus conference of 2006, revised in 2017, established some baseline clinical and radiological criteria, especially in terms of tumour size and associated lesions (lymphadenopathy), to guide the decision concerning the patient management (surveillance or surgical treatment). This consensus separated criteria in “worrisome” and “high-risk stigmata” that allow or not the surgical option [6]. These criteria, complemented by the European, American Gastroenterological Association and American College of Gastroenterology guidelines are an important decision-making aid [7–10].

The recent update of the European consensus, which is based on evidence-based medicine, describes the surgical indication criteria (relative and absolute) for operable patients [10]. In the absence of these criteria, surveillance (intensive or not) is recommended. This issue is becoming important because IPMN are now more frequently identified. For instance, in the present study, pancreatic resection for IPMN accounted for 18% of all pancreatic surgeries, and the indication for surgery was recurrent pancreatitis or suspicion of malignancy [21–23]. Eventually 50% of resected tumours were benign, suggesting that surveillance could have been a reasonable option for some of these patients. Moreover, morbidity and mortality rates in our series were not
negligible (15%). This represents an acceptable risk in the case of malignant disease, but debatable for benign disease.

We performed a retrospective analysis of all consecutive patients with IPMN who underwent surgery in our centre with the aim of evaluating the predictive value of the recent European consensus criteria [10] on the basis of the nature (benign vs malignant) of the resected IPMNs and the surgical morbidity/mortality.

First, analysis of the performance of the radiological and endoscopic criteria in our tertiary centre showed that they were in the same range as those previously published in pilot studies that display generally better performances [23–26]. MRCP and CT showed good performances to predict malignancies, whereas the results for EUS were slightly lower. This highlights the importance of combining complementary radiological investigations for the identification of the IMPN subtype and of malignant criteria, as previously demonstrated [27–29].

Second, we validated most of the absolute criteria that are significantly associated with the presence of malignancy (Table 4).

Table 4  Univariate and multivariate analyses of the absolute and relative criteria from the 2018 European evidence-based guidelines as predictors of malignant IPMN in the 124 patients with IPMN who underwent pancreatectomy

| Variables                              | Univariate analysis                                                                 | Multivariate analysis                                                                 |
|----------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
|                                        | OR  95% CI | p                  | OR  95% CI | p               |
| Jaundice                               | 7.76   (0.93–65.12) | 0.06               | 11.85 (1.17–119.79) | 0.04               |
| Benign (1–1.5%)                         | Malignant (7–11%)                                                                   |                                                                                       |
| Acute pancreatitis                     | 1.23   (0.50–3.01) | 0.65               | –                                                      |
| Benign (11–18%)                         | Malignant (13–21%)                                                                   |                                                                                       |
| New onset of diabetes                  | 0.31   (0.06–1.61) | 0.16               | 0.17 (0.03–1.09) | 0.06               |
| Benign (7–11%)                          | Malignant (2–3%)                                                                    |                                                                                       |
| Cyst ≥4 cm                              | 4.87   (2.10–11.30) | 0.0002             | 5.61 (2.02–15.5) | < 0.001             |
| Benign (6–10%)                          | Malignant (26–42%)                                                                   |                                                                                       |
| Cyst ≥3 cm (*)                         | 2.82   (1.34–5.96) | 0.007              | 2.78 (1.80–6.54) | 0.02               |
| Benign (30–48%)                         | Malignant (45–72.5%)                                                                  |                                                                                       |
| MD size 5–9.9 mm                        | 2.24   (1.08–4.64) | 0.03               | 4.77 (1.78–12.77) | 0.002              |
| Benign (20–38.5%)                       | Malignant (32–51.5%)                                                                  |                                                                                       |
| MD size ≥10 mm                          | 2.55   (1.15–5.64) | 0.02               | 7.52 (2.47–22.89) | 0.0004             |
| Benign (13–21%)                         | Malignant (25–40%)                                                                   |                                                                                       |
| Solid component                         | 1.90   (0.81–4.45) | 0.14               | 1.86 (0.67–5.20) | 0.24               |
| Benign (11–18%)                         | Malignant (18–29%)                                                                   |                                                                                       |
| Enhanced mural nodule > 5 mm           | 1.13   (0.43–3.01) | 0.80               | –                                                      |
| Benign (9–14.5%)                        | Malignant (10–16%)                                                                   |                                                                                       |
| Rapid progression                       | 0.75   (0.26–2.16) | 0.59               | –                                                      |
| Benign (9–14.5%)                        | Malignant (7–1%)                                                                     |                                                                                       |

Total histology: Benign, n = 62 (50%), Malignant n = 62 (50%)
OR: odds ratio; 95% CI: 95% confidence intervals; MD: main pancreatic duct
* This risk factor was included as worrisome feature in the 2012 Fukuoka consensus guideline
Statistical significant results are in bold
malignant IPMN, with PPV from 70 to 87%. However, we found that the combination of 2-3 absolute criteria does not provide any additional diagnostic value compared with each single criterion. Nevertheless, one absolute criterion should be considered as an indication of resection in operable patients.

Concerning the relative criteria, it seems that all criteria are not equally reliable. Two of them were significantly associated with malignancy with good predictive values (60 to 80%): cyst size ≥4 cm and Wirsung duct size between 5 and 10 mm. We found that cyst size ≥3 cm (previously chosen as cut-off value) was less sensitive, specific, and with lower predictive values than cyst size ≥4 cm, finally chosen by the EU guidelines. On the other hand, rapid growth of the lesion at imaging did not have a high diagnostic value in our study. This criterion was not included in the previous consensus conference, whereas it is an integral part of a recent Korean study on a large number of patients with longitudinal follow-up. The authors suggested that rapid growth can be a predictive criterion for malignancy, and recommended a strict imaging-based surveillance [30].

The main result of our analysis is that the combination of two or three relative criteria significantly increased

| Variables                          | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
|-----------------------------------|----------------------|----------------------|--------------|--------------|-------------------|
| Absolute criteria                 |                      |                      |              |              |                   |
| Solid component                   | 29% (18–41)          | 87% (76–94)          | 69% (48–85)  | 55% (44–65)  | 58% (46–71)       |
| Whipple/Total PT                  | 35%                  | 76%                  | 70%          | 43%          | 51%               |
| Jaundice                          | 11% (4–21)           | 98% (91–99)          | 87% (47–99)  | 52% (43–61)  | 55% (44–68)       |
| Whipple/Total PT                  | 15%                  | 97%                  | 88%          | 42%          | 46%               |
| Mural Nodule                      | 16% (8–27)           | 85% (74–99)          | 53% (28–75)  | 50% (40–60)  | 50% (42–61)       |
| Whipple/Total PT                  | 7%                   | 80%                  | 34%          | 35%          | 35%               |
| MD ≥ 10 mm                        | 39% (26–51)          | 84% (73–91)          | 71% (52–84)  | 58% (46–68)  | 61% (48–79)       |
| At least two criteria (n = 20)    | 24% (14–36)          | 91% (84–97)          | 75% (59–91)  | 55% (44–64)  | 58% (44–67)       |
| Whipple/Total PT                  | 31%                  | 76%                  | 67%          | 41%          | 48%               |
| At least three criteria (n = 9)   | 11% (4–21)           | 97% (88–96)          | 77% (40–97)  | 52% (42–61)  | 51% (40–60)       |
| Whipple/Total PT                  | 16%                  | 94%                  | 78%          | 41%          | 46%               |
| Relative Criteria                 |                      |                      |              |              |                   |
| Cyst ≥ 4 cm (*)                   | 42% (29–55)          | 90% (80–96)          | 81% (63–93)  | 61% (50–71)  | 66% (54–81)       |
| Whipple/Total PT                  | 53%                  | 76%                  | 78%          | 50%          | 62%               |
| MD 5–9.9 mm                       | 47% (34–60)          | 66% (53–77)          | 58% (43–72)  | 55% (43–67)  | 56% (44–71)       |
| Whipple/Total PT                  | 35%                  | 69%                  | 64%          | 40%          | 48%               |
| Acute pancreatitis                | 21% (11–36)          | 82% (72–91)          | 54% (43–66)  | 51% (41–61)  | 52% (43–64)       |
| Whipple/Total PT                  | 16%                  | 80%                  | 54%          | 38%          | 40%               |
| New onset of diabetes             | 3% (0.4–11)          | 88% (78–93)          | 22% (3–60)   | 48% (38–57)  | 46% (39–59)       |
| Whipple/Total PT                  | 9%                   | 83%                  | 45%          | 37%          | 38%               |
| Rapid growth rate                 | 1% (0.3–19)          | 83% (72–92)          | 37% (15–64)  | 48% (38–58)  | 47% (36–59)       |
| Whipple/Total PT                  | 11%                  | 90%                  | 63%          | 39%          | 42%               |
| At least two criteria (n = 30)    | 30% (19–43)          | 82% (70–90)          | 63% (43–80)  | 54% (43–64)  | 56% (45–68)       |
| Whipple/Total PT                  | 22%                  | 63%                  | 48%          | 34%          | 38%               |
| At least three criteria (n = 9)   | 14% (5–23)           | 100% (94–100)        | 100% (63–100) | 54% (44–62) | 57% (45–70)     |
| Whipple/Total PT                  | 9%                   | 100%                 | 100%         | 41%          | 44%               |

95% CI: 95% confidence interval
PPV: positive predictive value; NPV: negative predictive value
*: Cyst ≥3 cm (worrisome feature in the Fukuoka consensus guidelines 2012) had the following performances in the present study: sensitivity 66%, specificity 65%, PPV 65%, NPV 65% and accuracy 65%.
their diagnostic values with specificity and PPV values of 100%. All these elements should be considered, particularly if the risk of surgery complications is high.

However, due to the retrospective nature of our study it was difficult to take several c European consensus criteria into account in a formal way such as: assessing rapid growth of IPMN during the first 6 months after diagnosis, high grade dysplasia or malignant cytology, regular assessment of serum CA 19–9 level.

Our mortality rate was similar to that of other high volume centres [31]. We found, as expected, that extended pancreatic surgery (pancreatoduodenectomy and total pancreatectomy) is associated with higher morbidity. Therefore, decision-making should be very rigorous and evidence-based, especially when more extended surgery is planned. We also found that morbidity after extended surgery was higher in patients with benign IPMN. This can be explained by the fact that in benign IPMN, the soft consistency of pancreas and the absence of dilation of the MD increase the risk of fistulae [32].

For the first time, the 2018 European guidelines included the patient’s clinical condition and age in the decision-making balance; however, they do not consider the surgery type (and therefore the IPMN localization/diffusion) and the associated risks. Indeed, they recommend IPMN management in specialized high-volume centres; however, even in such centres.

For this reason, we propose that the surgery type should be an important criterion in the decision-making process. When the decision of extended or risky surgery is based only on relative criteria, we think that at least two or more should be present, or the EUS should be repeated by an expert and associated with FNA.

It would have been interesting to have a control group mainly composed of patients without any relative or absolute criteria. However, our series is a surgical retrospective one and this may be a selection bias: indeed patients (otherwise operable for pancreatic targeting) have been referred to our tertiary referral surgical center because of IPMN with symptoms and/or at least a relative or absolute resection criterion. Moreover, the rate of malignant IPMN in the present work is of 50%, which is significantly higher than observed in “watch and wait attitude” series (the cumulative incidence of malignancy at 5 and 10 years in series including patients with low-risk IPMN is 3.5 and 7.7% respectively) [33]. Another limitation of our is that the inclusion period is 10 years during which the resection criteria have evolved (i.e. Sendai consensus then Fukuoka consensus 2012–2017 [5, 6, 11]).

Conclusion
Our retrospective analysis of the performance of the absolute and relative criteria for IPMN malignancy shows that jaundice, cyst(s) ≥4 cm, and Wirsung duct diameter ≥ 10 mm are the most predictive absolute criteria of malignancy. Conversely, the diagnostic value of each isolated relative criterion is poor, and combining three relative criteria appears more relevant.

Considering the mortality and high morbidity rates of extended surgery (pancreatoduodenectomy and total pancreatectomy) particularly in patients with benign IPMN, we suggest integrating the type of surgical procedure in the decision-making algorithm for IPMN management. A prospective study integrating the morbidity of the surgical procedure would validate this decision-making algorithm.

Additional files

**Additional file 1:** Table S1. Diagnostic value of CT, MRCP and EUS for the preoperative diagnosis of IPMNs subtypes in 124 patients who underwent surgical resection (DOCX 69 kb)

**Additional file 2:** Table S2. Distribution of IPMN subtypes and malignancy depending of the pre-operative presence of relative and absolute criteria for resection according the European guidelines 2018 (DOCX 14 kb)

**Additional file 3:** Table S3. Surgery data and post-surgery complications for the 75 patients with IPMN who underwent duodenopancreatectomy (Whipple procedure) or total pancreatectomy. Data are shown for patients with benign (low-intermediate dysplasia) and malignant (high grade dysplasia –invasive carcinoma) IPMN (post-surgery pathology) (DOCX 56 kb)

Abbreviations
BD: Branch duct; CT: Computerized tomodesiemetry; EUS: Endoscopic ultrasound; FNA: Fine-needle aspiration biopsy; IPMN: Intraductal papillary mucinous neoplasm; MD: Main pancreatic duct; MRCP: Magnetic resonance cholangiopancreatography; NPV: Negative predictive value; PPV: Positive predictive value

Acknowledgments
Pr. Louis Buscail for critical reading of the manuscript.
The authors would like to thank Dr. Elisabetta Andermarcher for editing the English of the manuscript.

Authors’ contributions
EB conception, design, analysis, assembly and interpretation of data, manuscript writing; TC collection and assembly of data, interpretation of data; BF collection and assembly of data, interpretation of data; CB Statistical analyses; MM, BL, CS, JPA, VV analysis and interpretation of data; CL and LC conception, design, analysis, interpretation of data, final approval of the manuscript. All authors have read and approved the manuscript.

Funding
There are no resources of funding to be reported or declared.

Availability of data and materials
From the corresponding author on reasonable request.

Competing interest
No conflict of interest to declare.

Ethics approval and consent to participate
This study was conducted according the French rules (Bioethics law of November 2016 – research category number 3), and the Comité National Informatique et Liberté (French Data Protection Authority) recommendations for the anonymous extraction and treatment of data. According to these rules, due to the study retrospective nature, it was not necessary to obtain.
the patients’ informed consent for the analysis of their personal data. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th version, 2008).

Consent for publication
Not applicable

Author details
1Department of Digestive Surgery, Haut Leveque Hospital, University of Bordeaux, Bordeaux, France. 2Department of Epidemiology, BERN UMR INSERM INRA, University of Sorbonne Paris 13, Bobigny, France. 3Department of Pathology, Haut Leveque Hospital, University of Bordeaux, Bordeaux, France. 4Department of Radiology, Haut Leveque Hospital, University of Bordeaux, Bordeaux, France. 5Department of Gastroenterology and Endoscopy, Haut Leveque Hospital, University of Bordeaux, Bordeaux, France. 6INSERM 1035, University of Bordeaux, Bordeaux, France. 7Department of Surgery, Haut Leveque Hospital, Bordeaux, France.

Received: 31 May 2019 Accepted: 11 August 2019
Published online: 22 August 2019

References
1. Adsay V, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, et al. Pathologic evaluation and reporting of Intraductal papillary mucinous neoplasms of the pancreas and other Tumoral intraepithelial neoplasms of Pancreatobiliary tract: recommendations of Verona consensus meeting. Ann Surg. 2016;263:162–77.
2. Daudé M, Muscarl F, Buscail C, Carrère N, Otal P, Selves J, et al. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol. 2015;21:2658–67.
3. Malleg G, Marchegiani G, Borin A, Capelli P, Accordini F, Butturini G, et al. Observational study of the incidence of pancreatic and extrapancreatic malignancies during surveillance of patients with branch-duct intraductal papillary mucinous neoplasm. Ann Surg. 2015;262:984–90.
4. Lévy P, Jouannaud V, O’Toole D, Couvelard A, Vullierme MP, Palazzo L, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:460–8.
5. Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang J-Y, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatol Off J Int Assoc Pancreatol IAP Al. 2012;12:183–97.
6. Tanaka M, Fernández-del Castillo C, Kamitsawa T, Jang JY, Levy P, Ohtsu K, et al. Revisions of international consensus Fukuo guidelines for the management of IPMN of the pancreas. Pancreatol Off J Int Assoc Pancreatol IAP Al. 2017;17:738–53.
7. Vege SS, Ziring B, Jain R, Moayyedi P. Clinical Guidelines Committee, American Gastroenterology Association, American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:8819–22 quiz e1–2.
8. Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG clinical guideline: diagnosis and management of Pancreatic Cysts. Am J Gastroenterol. 2018;113:464–79.
9. Del Chiaro M, Verbeke C, Salvia R, Klöppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:703–11.
10. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:799–804.
11. Tanaka M, Chari S, Adsay V, Fernández-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatol Off J Int Assoc Pancreatol IAP Al 2006;6:17–32.
12. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
13. Bassi C, Marchegiani G, Derenvis C, Sarr M, Abul Haid M, Adham M, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula 11 years after. Surgery. 2017;161:584–91.
14. Wente MN, Viet JA, Bassi C, Derenski C, Finghent A, Gourna DJ, et al. Postpancreacteotomy hemorrhage (PPH): an international study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142:20–5.
15. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO. Classification of Tumours of the Digestive System. 4th ed: WHO - OMS, 2019. Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?codart=1&codal=70&ddchoc=4003.
16. Boum B, Kizrin S, Carrière N, Portier G, Otal P, Selves J, et al. Clinical fate of branch duct and mixed forms of intraductal papillary mucinous neoplasia of the pancreas. J Gastroenterol Hepatol. 2009;24:1211–7.
17. Jiang J-Y, Park T, Lee S, Kang MJ, Lee SY, Lee KB, et al. Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. BJS. 2014;101:686–92.
18. Marchegiani G, Andrianello S, Borin A, Dal Borgo C, Perri G, Pollini T, et al. Systematic review, meta-analysis, and a high-volume center experience supporting the new role of mural nodules proposed by the updated 2017 international guidelines on IPMN of the pancreas. Surgery. 2018;163:1272–9.
19. Ricci R, Casalder R, Tafurrelli G, Gani E, Pagano N, Picillo CA, et al. Risk factors for malignancy of branch-duct Intraductal papillary mucinous neoplasms: a critical evaluation of the Fukuo guidelines with a systematic review and meta-analysis. Pancreas. 2016;45:1243–54.
20. Casalder R, Ricci C, Tafurrelli G, Picillo CA, Migliori M, Minni F. Impact of surgery and surveillance in the management of branch duct intraductal papillary mucinous neoplasms of the pancreas according to Fukuo guidelines: the Bologna experience. Updat Surg. 2018;70:47–55.
21. Suzuki Y, Atomi Y, Sugiyama M, Isaji S, Imai K, Kimura W, et al. Cystic neoplasm of the pancreas: A Japanese multinational study of intraductal papillary mucinous tumor and mucinous cyst tumor. Pancreas. 2006;32:41–6.
22. Salvia R, Fernández-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678–85 discussion 685-687.
23. Ritidtit W, DelWitt JM, Schmidt CM, Roch A, Stuart JS, Sherman S, et al. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc. 2016;84:436–45.
24. Seo N, Byun JH, Kim JH, Kim HU, Lee SS, Song KB, et al. Validation of the 2012 international consensus guidelines using computed tomography and magnetic resonance imaging: branch duct and Main-duct Intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2016;263:557–64.
25. Kubo H, Chihiyaya T, Akahoshi K, Hamada S, Harada N, Sumii T, et al. Intraductal papillary-mucinous tumors of the pancreas: differential diagnosis between benign and malignant tumors by endoscopic ultrasonography. Am J Gastroenterol. 2001;96:1429–34.
26. Athgal G, Chy H, Cunningham JT, Durkalski V, Kim EY, Patel RS, et al. Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc. 2002;56:701–7.
27. Uribandi-Gonzalez L, Keane MG, Pereira SP, Iglesias-Garcia J, Domínguez-Muñoz JE, Lario-Noia A. Agreement among magnetic resonance imaging/ magnetic resonance cholangiopancreatography (MR-MRC) and endoscopic ultrasound (EUS) in the evaluation of morphological features of branch duct Intraductal papillary mucinous neoplasm (BD-IPMN). Pancreatol Off J Int Assoc Pancreatol IAP Al. 2018;18:170–5.
28. Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, et al. CT vs MRC - optimal classification of IPMN type and extent. J Gastroint Surg Off J Surg Soc Aliment Tract. 2008;12:101–9.
29. Robles EP-C, Maire F, Croix J, Vullerme M-P, Debrous V, Sauvenet A, et al. Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc. 2012;75:689–94.
30. Hong H, Lee J, Kim J, Kim H, Lee J, Ma T, et al. Progression of pancreatic branch duct Intraductal papillary mucinous neoplasm associates with cyst size. Gastroenterology. 2018;154:75–84.
31. Farges O, Bendersky N, Truant S, Delpero JR, Pruvot FR, Sauvanet A. The theory and practice of pancreatic surgery in France. Ann Surg. 2017;266:797–804.
32. Gaujoux S, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V, et al. Fatty pancreas. United European Gastroenterol J. 2016;4:580–91.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.